NeurAxis, Inc.

AMEX:NRXS

Biotechnology

Healthcare
$4.87 +4.25%

+$0.29 today

Market cap
$69.12M
Beta
1.41
P/E (TTM)
-10.5
EPS (TTM)
-$0.67
52W Low $2.20High $9.33

Volume 0.23M

Average 0.18M

NRXS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

NeurAxis, Inc.AMEX: NRXS

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns positive

Q1 FY2026 capital expenditures was $0, compared with -$18K a year earlier. Trailing-twelve-month capital expenditures was -$13.15K. Over 3 fiscal years it compounded at -20.2% a year.

Context

  • Capital expenditures amounted to 0.9% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$3.29K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$31.15K+12.1% YoY
LTMMar 2026
-$13.15K-57.7% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+12.1%——
3-year CAGR-20.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(31.15K) USD
Year-over-year change
-12.1%

Capital Expenditures vs competitors

How NRXS compares with its peers on the latest reported figures

  • NRXS's LTM Mar 2026 capital expenditures of $13.15K is the 2nd largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of -57.7% is the lowest of 2, against a peer median of -30.2%.
  • Capital expenditures amounts to 0.3% of revenue for NRXS, versus a peer median of 0.0%.
NRXS Competitors Peer median
Capital Expenditures for NRXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$71.94K -30.2%-79.7%—
NRXSNeurAxis, Inc.LTM Mar 2026$13.15K -57.7%-20.2%0.3%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
RLYBRallybio CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding NRXS) $0-30.2%-79.7%0.0%

Competitors are the stored peer set for NRXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(3.03M)(4.78M)(14.63M)(8.24M)(7.8M)
Depreciation & Amortization36.71K37.13K40.73K37.83K59.5K
Deferred Income Tax41.11K0000
Stock-Based Compensation48.64K27.32K750K1.4M596.85K
Change in Working Capital644.43K1.27M(665.75K)141.4K610.12K
Accounts Receivables184.26K(78.6K)75.95K(178.85K)46.59K
Inventory67.67K(8.95K)26.91K(32.5K)(242.87K)
Accounts Payables319.23K1.11M(387.9K)(607.27K)(457.58K)
Other Working Capital73.28K249.62K(380.71K)960.02K1.26M
Other Non-Cash Items22.81K1.15M7.81M559.82K101.24K
Operating Cash Flow(2.23M)(2.3M)(6.69M)(6.1M)(6.43M)
Capital Expenditures(1.39K)(61.21K)(71.78K)(27.78K)(31.15K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(59.82K)(41K)0(100K)
Investing Cash Flow(1.39K)(61.21K)(71.78K)(27.78K)(131.15K)
Debt Repayment151.1K3.16M2.07M4.66M(281.75K)
Common Stock Issued510K04.85M08.83M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(510K)(866.74K)(322.9K)(168.32K)(712.67K)
Financing Cash Flow661.1K2.29M6.59M9.74M7.83M
Effect of Forex Changes00000
Net Change in Cash(1.57M)(67.16K)(175.14K)3.62M1.27M
Free Cash Flow(2.24M)(2.36M)(6.77M)(6.13M)(6.46M)

NeurAxis, Inc.

AMEX:NRXS

Intrinsic Alpha fair value

Locked

Current Price

$4.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.